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Osteoblastoma is a benign bone tumor that can often be difficult to distinguish from malignant 
osteosarcoma. Because misdiagnosis can result in unfavorable clinical outcomes, we have 
investigated microRNAs as potential diagnostic biomarkers for distinguishing between these two 
tumor types. Next generation RNA sequencing was used as an expression screen to evaluate 
>2,000 microRNAs present in tissue derived from rare formalin fixed paraffin embedded (FFPE) 
archival tumor specimens. MicroRNAs displaying the greatest ability to discriminate between 
these two tumors were validated on an independent tumor set, using qPCR assays. Initial screening 
by RNA-seq identified four microRNA biomarker candidates. Expression of three miRNAs 
(miR-451a, miR-144-3p, miR-486-5p) was higher in osteoblastoma, while the miR-210 was 
elevated in osteosarcoma. Validation of these microRNAs on an independent data set of 22 tumor 
specimens by qPCR revealed that miR-210 is the most discriminating marker. This microRNA 
displays low levels of expression across all of the osteoblastoma specimens and robust expression 
in the majority of the osteosarcoma specimens. Application of these biomarkers to a clinical test 
case showed that these microRNA biomarkers permit re-classification of a misdiagnosed FFPE 
tumor sample from osteoblastoma to osteosarcoma. Our findings establish that the hypoxia-related 
miR-210 is a discriminatory marker that distinguishes between osteoblastoma and osteosarcoma. 
This discovery provides a complementary molecular approach to support pathological 
classification of two diagnostically challenging musculoskeletal tumors. Because miR-210 is 
linked to the cellular hypoxia response, its detection may be linked to well-established pro-
angiogenic and metastatic roles of hypoxia in osteosarcomas and other tumor cell types.
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Osteoblastoma is a locally aggressive bone tumor that can be treated with local curettage 
without the need for radiation or chemotherapy. In contrast, osteosarcoma is a life 
threatening malignancy requiring wide surgical resection and chemotherapy. Although these 
tumors exhibit very different clinical behaviors, they can appear histologically and 
radiographically similar, making them difficult to differentiate clinically. Osteosarcoma is 
the most common primary malignant bone tumor in children and adolescents.1 It typically 
involves the metaphyseal region of long bones, and most frequently arises within the femur, 
tibia, or humerus.2 Osteoblastoma is a rare primary bone tumor, accounting for 
approximately 1% of all bone tumors.3 It is most likely to present in the 3rd to 4th decade of 
life, where it commonly affects the posterior elements of the spine.4,5 Although 
osteosarcoma and osteoblastoma have a predilection for different anatomic sites, each of 
these tumors can occur within any bone and can affect patients at any age. When 
misdiagnosis does occur, the results can be catastrophic resulting in unnecessary surgical 
resections with high morbidity (i.e., amputation), or even death when osteosarcomas are 
inadequately treated.
Because of the histological similarities and potential for misdiagnosis between 
osteoblastoma and high-grade osteosarcoma, there is a compelling need to improve current 
multi-disciplinary diagnostic methods (including clinical, histological, and radiographic 
findings) by developing precise molecular biomarkers. Recurrent chromosome 22 loss in 
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osteoblastoma, which encompasses loci for Wnt signaling inhibitors, has been investigated 
as a biomarker to differentiate between osteosarcoma and osteoblastoma. This chromosomal 
alteration is associated with high canonical Wnt signaling and alterations in beta-catenin in 
osteoblastoma that may facilitate tumor diagnosis.6–8 Despite their utility, these biomarkers 
are not definitive and have not yet gained widespread acceptance for routine clinical use. 
Key impediments to biomarker development are the rarity of osteoblastomas compared to 
osteosarcomas, and the resulting limited availability of patient biopsies. Consequently, 
studies are restricted to archived formalin-fixed paraffin embedded biopsies and analysis of 
selected candidate genes and proteins. Additionally, these tumors frequently need to be de-
calcified using harsh reagents prior to paraffin embedding that can limit the utility of 
conventional staining techniques. Yet, microRNAs, which are small noncoding RNAs (20–
24 nucleotides in length) that act as post-transcriptional regulators of gene expression, are 
sufficiently stable for detection in de-calcified archival specimens.
MicroRNAs display aberrant expression patterns in a wide array of tumors including 
osteosarcoma.9 Their small size makes these molecules highly resistant to degradation and 
potentially versatile clinical biomarkers for tumor diagnosis.10 Studies have shown that 
micro-RNAs can be reliably extracted from FFPE tumor specimens that have been stored for 
decades, and that expression profiles correlate well with fresh frozen specimens.11 Several 
studies have examined microRNA expression in osteosarcoma and directly correlated 
changes in microRNA levels with clinical outcomes and response to chemotherapy.12–15 
These studies suggest that microRNAs may be effective biomarkers for orthopedic tumors, 
although it is not clear yet whether miRNAs can be used to differentiate between 
osteosarcoma and osteoblastoma. Because of the clinical importance of accurately 
diagnosing osteosarcoma and osteoblastoma, we performed a high-resolution expression 
screen using RNA sequencing (RNA-seq) to examine which of the more than 2,000 
currently known miRNAs in the human genome can differentiate between these two 
clinically challenging tumors. The main finding of this study is the definition of a novel 
bone tumor signature that permits clinical separation and correct classification of 
osteoblastoma versus osteosarcoma.
METHODS
Tumor Collection and RNA Isolation
A total of 30 FFPE tumor specimens (16 osteosarcomas and 14 osteoblastomas) were 
collected for research use from either Mayo Clinic or Leiden University Medical Center 
(LUMC). The osteosarcomas included, one osteoclast-rich, two chondroblastic, and 13 
osteoblastic subtypes. The histology and x-ray radiographs for each tumor specimen was 
evaluated by a trained musculoskeletal pathologist (JT or JB), to ensure the correct tumor 
diagnosis, and that representative areas of the tumor were sampled. The 12 tumor specimens 
obtained from LUMC were also stained for beta-catenin using previously described 
methods.7,8
For RNA isolation a total of three, 10 micron sections were cut from each paraffin block. 
Tumor cells were macro-dissected from each section and subsequently used for micro-RNA 
isolation. None of the tumors evaluated in this investigation had been treated with pre-
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operative chemotherapy or radiation. FFPE sections were deparaffinized using xylene, and 
microRNAs were extracted using the Qiagen miRNeasy FFPE kit (Qiagen, Hilden, 
Germany). Total RNA was quantified using the NanoDrop 2000 spectrophotometer (Thermo 
Fischer Scientific, Wilmington, Delaware). RNA samples were subsequently examined by 
RNA-seq analysis and/or real-time quantitative PCR. All human tumor specimens used in 
this study were collected in compliance with ethical standards for research and were in 
compliance with the rules and institutional guidelines governing human subjects research 
(IRB #11-008574, “Differentiating musculo-skeletal tumors using microRNA expression 
profiling”).
RNA Sequencing and Bioinformatics Analysis
High-throughput next generation microRNA sequencing was performed using five 
osteoblastoma, and four osteosarcoma specimens (three osteoblastic subtypes and one 
chondroblastic subtype). MicroRNAs were sequenced using the NEBNext Small RNA 
library prep kit on an Illumina HiSeq 2000. Short reads were trimmed of adapters with 
Cutadapt.16 Trimmed microRNA sequences greater than 17 nucleotides in length were then 
aligned to the reference genome and miRBase reference sequences using Bowtie.17 Known 
micro-RNA expression and novel microRNA prediction and quantification were performed 
using miRDeep2.18 All secondary data analyses were carried out using robustly expressed 
microRNAs, with an average expression of at least 10 normalized reads per million in either 
the osteoblastomas or osteosarcomas. Unsupervised hierarchical clustering was performed 
using the Pearson correlation method. MicroRNA target prediction was performed using 
ComiR, a combinatorial microRNA analysis program that takes into account microRNA 
expression levels was used for computational target prediction19,20 for microRNAs that 
showed a greater than threefold difference in expression between osteosarcoma and 
osteoblastoma. Functional gene annotation was performed for genes differentially expressed 
between osteoblastoma and osteosarcoma using the Database for Annotation and 
Visualization and Integrated Discovery v6.7 (DAVID 6.7).21,22
PCR Validation of MicroRNA Biomarkers
Selected microRNAs that were differentially expressed based on RNA-seq data were 
validated using TaqMan® microRNA assays (Life Technologies, Carlsbad, California). Real-
time qPCR reactions were performed using the CFX384 Real-Time qPCR System (BioRad). 
Ribosomal RNA U6 and miR-103a-3p were included as reference genes. All microRNAs 
were normalized to miR-103a-3p, because this miRNA showed the lowest variability based 
on our RNA-seq analysis. MicroRNA expression levels were quantified using the 2ΔCt 
method. TaqMan® microRNA assays were used for U6 snRNA, hsa-miR-103, hsa-
miR-320c, hsa-miR-210, hsa-miR-451, hsa-miR-144-3p, hsa-miR-486-5p, and hsa-
miR-144-5p (Life Technologies, Carlsbad, California). Samples with poor amplification (Ct 
values greater than 35 for miR-103a-3p) were excluded, in total two samples were omitted.
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Evaluation of MicroRNA Sequencing Data from FFPE Tumors Specimens
To determine if microRNA profiles were different between osteosarcoma and osteoblastoma, 
we performed unsupervised hierarchical clustering on tumor specimens using 
comprehensive microRNA profiles consisting of 2,252 human annotated microRNA 
sequences. The clustering dendrogram showed a trend toward independent grouping of the 
osteoblastomas and osteosarcomas (Fig. 1). A direct comparison of FFPE tumor specimens 
showed 76 microRNAs with greater than threefold expression in osteosarcoma compared to 
osteoblastoma (Supplementary Table S1), and 42 microRNAs enriched greater than 
threefold in osteoblastoma versus osteosarcoma (Supplementary Table S2).
To determine if differentially expressed microRNAs are representative of the underlying 
tumor biology, we examined possible gene targets for differentially expressed microRNAs 
that may contribute to the benign versus malignant behavior in osteoblastoma and 
osteosarcoma, respectively.23 ComiR analysis was performed using microRNAs that showed 
at least a threefold difference in expression between osteoblastoma and osteosarcoma. We 
identified the top 1,000 genes that were predicted to be preferentially targeted in both 
osteoblastoma and osteosarcoma (Supplementary Table S3). Gene ontology analysis 
(DAVID 6.7) was used to identify regulatory pathways controlled by predicted gene targets. 
Genes linked to mitosis, lipid metabolism, transcription, and protein synthesis were 
predicted to be targeted by microRNAs enriched in osteoblastoma. In contrast, genes linked 
to apoptosis and lymphocyte activation were predicted to be inhibited by microRNAs 
enriched in osteosarcoma (Fig. 2). This preliminary analysis identifies microRNA regulatory 
mechanisms that may be acting to promote the benign and malignant behaviors of these two 
respective tumors, further work to validate underlying mechanisms is required before 
definitive conclusions can be made.
To refine the diagnostic accuracy of this initial analysis, we focused on microRNAs with the 
greatest ability to discriminate between osteosarcoma and osteoblastoma. Our approach 
ultimately aims to convert the high-throughput RNA sequencing data into a clinical test that 
can interrogate a select group of diagnostic microRNAs using qPCR and be readily 
performed at most medical centers. Such a test would be more affordable and less time 
consuming but not require specialized sequencing equipment. To develop this qPCR-based 
assay, we identified microRNA candidates that were abundantly expressed (>500 normalized 
reads in either osteoblastoma or osteosarcoma samples) with the greatest differential 
expression (>5-fold change) between osteosarcoma and osteoblastoma based on RNA 
sequencing data. Four microRNAs, miR-210, miR-486-5p, miR-451a, and miR-144-3p met 
these criteria (Fig. 3A).
qPCR Normalization
Sample normalization is critical for ensuring the consistency of a diagnostic qPCR test. 
Ribosomal RNA U6 is commonly used as a normalizer in microRNA studies. But because it 
is larger in size than micro-RNAs, it is more susceptible to degradation and may show 
variable expression across FFPE tumor samples because of differences in sample handling, 
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processing, and storage. Therefore, we selected a microRNA for normalization that is highly 
expressed but shows relatively little variation across FFPE tumor samples. When analyzing 
the RNA-seq data, we limited our search to microRNAs that were robustly expressed at 
greater than 1,000 normalized reads per million, and then sorted these samples according to 
the coefficient of variation (Fig. 4). MiR-103a-3p showed the least amount of variation 
across tumor specimens. In addition, miR-103a-3p has also been reported as a reliable 
normalization factor in other publications, and has been applied to other tumor biomarker 
studies.24 Based on our sequencing data, and previous reports demonstrating its reliability, 
we chose to use miR-103a-3p for qPCR normalization in this investigation.
qPCR Validation Using TaqMan Assays
Because archival tumor specimens are an exceedingly valuable resource with low RNA 
yields, we performed highly sensitive qPCR TaqMan assays to maximize the amount of 
molecular data that could be obtained from each tumor specimen. qPCR was initially 
performed on the eight tumor samples used for RNA sequencing to confirm the accuracy and 
differential expression of our candidate microRNA biomarkers. RNA-seq and qPCR 
quantification showed excellent concordance with very similar distributions across sample 
groups (Fig. 3B). These findings establish the reliability of qPCR as a diagnostic tool for 
discriminating microRNA biomarkers that are differentially expressed between 
osteosarcoma and osteoblastoma.
An independent set of 22 additional FFPE tumor samples (11 osteosacomas and 11 
osteoblastomas) were obtained by combining archival specimens collected from two 
separate institutions. These specimens were used to validate the diagnostic accuracy of the 
four microRNA biomarker candidates. RNA from tumor specimens that did not amplify 
efficiently (Ct values greater than 35 for miR-103a-3p) were excluded from further analysis 
(in total two osteoblastoma specimens were excluded). Statistically significant differential 
expression of miR-210 was confirmed by qPCR validation (Fig. 5). A receiver operating 
characteristic (ROC) curve, displaying favorable biomarker characteristics, was generated 
for miR-210 using qPCR expression data, the curve displays favorable biomarker 
characteristics (Area under the curve (AUC) of 0.8182, p = 0.0167) (Fig. 6).
To determine if miR-210 could be useful in discriminating between osteosarcomas and 
osteoblastomas in cases where diagnosis is especially challenging, we applied microRNA 
biomarkers to a historical test case. This specimen represents an osteoblastic osteosarcoma 
that was initially diagnosed as an osteoblastoma, and later confirmed to be an osteosarcoma 
after tumor recurrence and lung metastasis. qPCR analysis shows that miR-210 is elevated in 
this tumor specimen at a level that is not observed in any of the osteoblastoma specimens 
(Fig. 7), a finding that is also reflected in our specificity calculations (Fig. 5). The 
microRNAs miR-320c and miR-144-5p were included as outgroups in this evaluation, and 
as expected, did not show statistically significant differences in expression between tumor 
types. Based on these observations, the microRNA biomarkers from this investigation would 
have been potentially informative for this clinical case, and could have favorably altered this 
patient’s diagnostic workup and treatment plan.
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Recent studies have proposed β-catenin as a promising marker to distinguish between 
osteosarcomas and osteoblastomas.7 Osteosarcomas have been shown to have reduced Wnt 
signaling, and associated cytoplasmic beta-catenin staining in comparison with 
osteoblastomas which are more likely to display nuclear staining.6–8 To investigate whether 
miR-210 expression can be applied as a useful adjunct to beta-catenin staining, we compared 
miR-210 expression in various osteosarcoma and osteoblastoma specimens that we had 
stained for beta-catenin. Our studies reaffirm previous work8 that beta-catenin staining is a 
useful marker for differentiating between osteoblastomas and osteosarcomas. When we 
compared miR-210 expression across tumor specimens where beta-catenin staining did not 
indicate the proper diagnosis we found that miR-210 expression favored the correct 
diagnosis (Table 1). Thus, miR-210 expression is potentially a useful biomarker that can be 
used in conjunction with beta-catenin staining to help clarify nondiagnostic cases or provide 
a warning when beta-catenin staining may be favoring the incorrect diagnosis.
DISCUSSION
Musculoskeletal tumors present unique challenges, because the differential diagnosis is 
often very broad and encompasses both benign and malignant lesions. Determining an 
accurate diagnosis and formulating an optimal treatment plan is critical for achieving good 
clinical outcomes for patients. This investigation provides evidence that microRNAs can be 
used as biomarkers to help distinguish between osteoblastomas and malignant 
osteosarcomas, and provides further support for the use of microRNAs as diagnostic markers 
for differentiating between other musculoskeletal tumors.
Our present findings can be further appreciated within the broad context of previous and 
current methods that define molecular biomarkers in osteosarcoma cells and clinical 
biopsies, as well as to refine diagnostics and treatment modalities. Collaborative studies 
from our group and others are representative of different molecular strategies that have been 
used for biochemical analyses of osteosarcomas. These studies include proteomic 
characterization of nuclear proteins,25,26 candidate analysis of changes in regulatory proteins 
or miRNAs linked to osteoblast growth and bone cancer,27–33 cytogenetic analysis of 
chromosomal aberrations,34,35 in situ analysis of gene expression for selected markers,36 as 
well as microRNA profiling.13,15 Together with many other studies that have been 
summarized in a large automated database focusing on the molecular pathology of 
osteosarcoma,37 there is now relatively broad (albeit not necessarily deep) knowledge of 
proteins, genes, and miRNAs that are phenotypically and/or causally linked to osteosarcoma. 
This paucity of molecular studies to date is presumably due to the extreme rarity of the 
disease and difficulties in procuring adequate tissue samples. Our present findings that 
leverage unique archived osteoblastoma specimens, which were derived from two tertiary 
referral centers, may have significant impact on diagnosis and future mechanistic studies of 
osteoblastoma as a still poorly understood bone tumor.
Elevated expression of miR-210, which is a hypoxia-induced microRNA controlled by 
hypoxia inducible factor 1α (HIF1A), is known to be enriched in osteosarcoma.38 Increased 
levels of this miRNA are a molecular proxy marker for reduced relative levels of oxygen in 
cells and tissues. Recent investigations suggest that miR-210 has important prognostic 
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implications, with higher expression being associated with unfavorable long-term 
survival.39,40 Osteoblastomas are known to be highly vascular well-perfused tumors, and 
could be expected to express lower levels of miR-210 as we indeed observed in this study. 
Hypoxia inducible factor has been previously proposed as a biomarker for osteosarcoma, 
and our findings corroborate this concept. Yet, the advantage of miR-210 is its greater 
stability and reliable detection in archival FFPE specimens, even after treatment with harsh 
decalcifying agents.
Differences in surgical technique and tumor processing can potentially impact the expression 
of micro-RNAs in FFPE specimens. These technical issues have the potential to render 
microRNA expression signatures more variable across institutions, potentially limiting their 
diagnostic potential. However, the hypoxia-related miR-210, may indeed be highly specific 
for osteosarcoma compared to osteoblastoma. Osteoblastomas have a rich vascular supply 
and do not appear to express high-levels miR-210, while the majority of osteosarcomas we 
have analyzed exhibit elevated expression of miR-210. It is conceivable that biopsy sampling 
error and differences in tissue handling may lead to test results showing low levels of 
expression of miR-210 in an osteosarcoma biopsy (false negative result). The hypoxia-
dependent expression of miR-210 ensures that false positive results for osteoblastoma 
detection are unlikely. While negative results remain inconclusive, positive identification of 
robust miR-210 expression provides a novel diagnostic indicator that favors radical surgical 
intervention. Because the hypoxia response is a highly conserved and ubiquitous cell 
autonomous response, anatomic location alone cannot account for the differential expression 
of miR-210 seen between osteosarcoma and osteoblastoma. The anatomy independent 
expression of miR-210 further supports its application as a discriminating tumor biomarker.
Even though miR-210 is a useful diagnostic aid, its expression remains a quantitative 
measurement and some osteosarcomas have levels that do not differ from osteoblastomas. 
Osteoblastomas occur preferentially in the posterior elements of the spine, which has a 
robust blood supply to support the spinal cord, which could potentially suppress miR-210 
expression. The misdiagnosed osteoblastic osteosarcoma that we evaluated earlier (Fig. 7) 
was also located in the posterior elements of the spine, but the robust expression of miR-210 
in this specimen is on the low range of expression levels detected in other osteosarcoma 
tissues, consistent with this tumor being derived from a highly vascularized environment.
It is important to note that microRNA expression profiles not only reflect what tumor cells 
are producing, they also provide important information regarding the tumor 
microenvironment, and neighboring cells that support tumor growth. Musculoskeletal 
tumors can appear histologically as a heterogeneous mixture of cells, and for many 
musculoskeletal lesions (i.e., chondroblastoma, giant cell tumor) the causative tumorigenic 
cell is often elusive. Thus, the microRNAs which take into account tumor 
microenvironment, as well as the tumor cells themselves are informative markers for tumor 
diagnosis. It would be premature to conclude that the tumor specific microRNAs identified 
in this investigation play a mechanistic role in tumor pathogenesis. However, miR-210 has 
been shown to suppress Wnt signaling41 and may play a role in the known downregulation 
of Wnt signaling observed osteosarcomas.8
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MicroRNAs such as miR-210 identified in this investigation are well suited for use as 
clinical bio-markers. They have several advantages over traditional biomarkers in that they 
are highly stable and can be isolated from archived formalin fixed paraffin embedded tumor 
specimens that are routinely use in clinical practice. Our studies show that miRNAs maintain 
their integrity even after being treated with JVMGB—Provided surgical specimens and 
reviewed tumor histology for the study. Participated in the design of the study, interpreted 
data, prepared and approved final manuscript. AJvW—Participated in the design of the 
study, interpreted data, prepared and approved final manuscript.
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An overview of microRNA sequencing results. Unsupervised hierarchical clustering using 
the Pearson correlation method was performed on comprehensive microRNA sequencing 
data consisting of 2,252 microRNA sequences, from FFPE osteosarcoma and osteoblastoma 
tumor specimens. The clustering dendogram shows independent clustering of the 
osteosarcoma and osteoblastoma FFPE specimens, suggesting that microRNA biomarkers 
may be effective in discriminating between these two tumors.
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ComiR analysis of microRNA targets in osteoblastoma and osteosarcoma. To determine if 
microRNAs differentially expressed between osteoblastoma and osteosarcoma reflect 
underlying tumor biology, we carried out functional gene annotation clustering using 
DAVID 6.7 for predicted microRNA targets generated using ComiR. Functional gene 
clusters were created for all gene targets in osteoblastoma and osteosarcoma combined, and 
then for osteosarcoma and osteoblastoma separately, to determine which tumor type 
contributes most toward each functional gene cluster. This analysis shows that genes 
controlling mitosis, lipid metabolism, transcription, and protein synthesis were predicted to 
be targeted by microRNAs enriched in osteoblastoma. In contrast, genes linked to apoptosis 
and lymphocyte activation were predicted to be inhibited by microRNAs enriched in 
osteosarcoma.
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Identification of microRNA biomarker candidates using RNA-seq. (A) MicroRNA 
sequencing identified three micro-RNAs, miR-486-5p, miR-451a, and miR-144-3p, as 
having an average expression greater than 500 normalized reads per million, and a 
statistically significant fold change enrichment greater than fivefold compared with 
osteosarcoma. MiR-210 was the only microRNA to show a statistically significant fold 
change greater than fivefold in osteosarcoma, and was found to have an average expression 
level 20 times higher in osteosarcoma compared with osteoblastoma. Based on their 
differential expression patterns, these four microRNAs were selected for further qPCR 
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validation. (B) qPCR validation of the same tumor samples used for RNA-seq confirmed 
differential expression of these four microRNA biomarker. Expression data showed good 
concordance with RNA-seq results, showing similar variability and distribution for each 
tumor type. Statistical significance was evaluated using the Wilcoxon rank-sum test, a p-
value <0.05 is indicated by an “*”. Error bars are given as ±1 standard deviation from the 
mean.
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The established microRNA normalizer miR-103a-3p showed the least amount of variance 
among robustly expressed (>1,000 normalized reads per million) microRNAs across FFPE 
tumor specimens and was, therefore, chosen as the primary normalizer for this investigation.
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Validation of microRNA biomarkers using an independent data set of 20 FFPE tumor 
specimens. qPCR validation of microRNA biomarker candidates identified by our initial 
RNA-Seq screen, confirmed statistically significant differential expression of miR-210 
between osteoblastoma and osteosarcoma. Statistical significance was evaluated using the 
Wilcoxon rank-sum test a p-value <0.05 is indicated by an “*”. Error bars are given as ±1 
standard deviation from the mean.
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A receiver operating characteristic (ROC) curve was generated using all 28 tumor specimens 
that produced interpretable expression data for miR-210. The ROC curve displays favorable 
characteristics for a diagnostic biomarker with an AUC of 0.8182 (p = 0.0167).
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qPCR expression data for all 28 tumor specimens evaluated in this investigation. The 
diagnostic utility of miR-210 was tested on an osteoblastic osteosarcoma biopsy that was 
initially thought to be a vertebral osteoblastoma based on clinical, radiographic, and 
histologic criteria. The misdiagnosed osteosarcoma specimen had a qPCR expression level 
for miR-210 of 33.81 (normalized to miR-103a-3p), which is higher than any osteoblastoma 
we evaluated in this investigation, and corresponds to a specificity of 100% based on our 
ROC curve (Fig. 6). The additional microRNAs were evaluated as outgroups, and did not 
show differential expression between tumor types. Statistical significance was evaluated 
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using the Wilcoxon rank-sum test, a p-value <0.05 is indicated by an “*”. Error bars 
represent the interquartile range (25–75%).
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Table 1
A Comparison of Beta-Catenin Staining and miR-210 as Discriminating Markers for Osteoblastoma and 
Osteosarcoma
Tumor Type Consensus Pathology Review miR-210 Expression (/miR-103a-3p)
miR-210 Classification (Based on IQR 25–
75%)
Osteosarcoma Cytoplasmic 72.25 Osteosarcoma
Osteosarcoma Cytoplasmic 64.66 Osteosarcoma
Osteosarcoma Cytoplasmic 37.65 Osteosarcoma
Osteosarcoma Cytoplasmic 14.28 Osteosarcoma
Osteosarcoma Focal nuclear 58.35 Osteosarcoma
Osteosarcoma Cytoplasmic 6.39 Osteoblastoma
Osteosarcoma Cytoplasmic 157.97 Osteosarcoma
Osteoblastoma Nuclear 4.14 Osteoblastoma
Osteoblastoma Nuclear 10.75 Nondiagnostic
Osteoblastoma Nuclear 27.33 Osteosarcoma
Osteoblastoma Focal nuclear 7.42 Osteoblastoma
Osteoblastoma Nuclear 7.17 Osteoblastoma
These results confirm findings from previous studies showing beta-catenin as a discriminating marker for osteoblastoma and osteosarcoma. In cases 
where beta-catenin staining is equivocal (highlighted cases) miR-210 expression is able to indicate the proper diagnosis. These findings show that 
miR-210 expression levels can be used in conjunction with beta-catenin staining to improve the accuracy of tumor diagnosis.
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